For the quarter ended March 2023, Kimberly-Clark (KMB - Free Report) reported revenue of $5.2 billion, up 2% over the same period last year. EPS came in at $1.67, compared to $1.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.08 billion, representing a surprise of +2.22%. The company delivered an EPS surprise of +24.63%, with the consensus EPS estimate being $1.34.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Kimberly-Clark performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Organic Sales Growth - YoY change: 5% versus the four-analyst average estimate of 3.36%.
- K-C Professional & Other - Total Sales Growth - YoY change: 9% versus the three-analyst average estimate of 5.08%.
- Personal Care - Net price impact - YoY change: 7% compared to the 5.95% average estimate based on three analysts.
- Personal Care - Currency impact - YoY change: -4% versus the three-analyst average estimate of -3.4%.
- Consumer Tissue - Volume impact - YoY change: -5% compared to the -5.79% average estimate based on three analysts.
- Consumer Tissue - Net price impact - YoY change: 11% versus the three-analyst average estimate of 10.59%.
- Consumer Tissue - Currency impact - YoY change: -3% compared to the -3.26% average estimate based on three analysts.
- K-C Professional & Other - Volume impact - YoY change: -6% compared to the -4.78% average estimate based on three analysts.
- Net Sales- Personal Care: $2.70 billion versus $2.65 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
- Net Sales- K-C Professional & Other: $847 million compared to the $819.58 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year.
- Net Sales- Corporate & Other: $10 million versus the three-analyst average estimate of $16.65 million. The reported number represents a year-over-year change of -44.4%.
- Net Sales- Consumer Tissue: $1.63 billion versus $1.59 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.
View all Key Company Metrics for Kimberly-Clark here>>>Shares of Kimberly-Clark have returned +10% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
For the quarter ended March 2023, Kimberly-Clark (KMB - Free Report) reported revenue of $5.2 billion, up 2% over the same period last year. EPS came in at $1.67, compared to $1.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.08 billion, representing a surprise of +2.22%. The company delivered an EPS surprise of +24.63%, with the consensus EPS estimate being $1.34.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Kimberly-Clark performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Organic Sales Growth - YoY change: 5% versus the four-analyst average estimate of 3.36%.
- K-C Professional & Other - Total Sales Growth - YoY change: 9% versus the three-analyst average estimate of 5.08%.
- Personal Care - Net price impact - YoY change: 7% compared to the 5.95% average estimate based on three analysts.
- Personal Care - Currency impact - YoY change: -4% versus the three-analyst average estimate of -3.4%.
- Consumer Tissue - Volume impact - YoY change: -5% compared to the -5.79% average estimate based on three analysts.
- Consumer Tissue - Net price impact - YoY change: 11% versus the three-analyst average estimate of 10.59%.
- Consumer Tissue - Currency impact - YoY change: -3% compared to the -3.26% average estimate based on three analysts.
- K-C Professional & Other - Volume impact - YoY change: -6% compared to the -4.78% average estimate based on three analysts.
- Net Sales- Personal Care: $2.70 billion versus $2.65 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
- Net Sales- K-C Professional & Other: $847 million compared to the $819.58 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year.
- Net Sales- Corporate & Other: $10 million versus the three-analyst average estimate of $16.65 million. The reported number represents a year-over-year change of -44.4%.
- Net Sales- Consumer Tissue: $1.63 billion versus $1.59 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.
View all Key Company Metrics for Kimberly-Clark here>>>Shares of Kimberly-Clark have returned +10% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on KMB - FREE